Sanofi shakes up clinical plans for trio of programs from Denali, Principia and Kymab deals

Sanofi is shuf­fling its pipeline af­ter sev­er­al tri­al flops in an­ti-in­flam­ma­to­ry and can­cer drugs it land­ed through a part­ner­ship with De­nali and buy­outs of Prin­cip­ia and Kymab.

In its third-quar­ter re­port, Sanofi dis­closed it end­ed en­roll­ment in a study in­ves­ti­gat­ing alom­fil­imab, an an­ti-ICOS mAb that it got from its $1.5 bil­lion Kymab buy­out, for the treat­ment of sol­id tu­mors. The de­ci­sion was not based on any ob­served safe­ty sig­nal, the com­pa­ny added, though it didn’t pro­vide any more de­tails.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.